Xeris Biopharma Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Stockholders held by Xeris Biopharma Holdings, Inc. on June 4, 2025. As of the record date of April 14, 2025, there were 156,384,578 shares of common stock outstanding, with 111,098,912 shares represented at the meeting, establishing a quorum.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
The following proposals were submitted to a vote of security holders:
- Proposal One: Election of Directors - Three Class I director nominees were elected by a plurality vote to serve until the 2028 Annual Meeting:
- BJ Bormann: 57,050,196 For; 21,676,213 Withhold.
- James Brady: 76,465,887 For; 2,260,522 Withhold.
- Garheng Kong: 75,938,627 For; 2,787,782 Withhold.
- Proposal Two: Ratification of Auditors - Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Results: 110,053,757 For; 744,492 Against; 300,663 Abstain.
- Proposal Three: Say-on-Pay Vote - Stockholders approved, on a non-binding advisory basis, the compensation of Named Executive Officers.
- Results: 72,202,176 For; 5,633,615 Against; 890,618 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Confirmation that Ernst & Young LLP is the appointed auditor for the fiscal year ending December 31, 2025.
- Verification of the new Class I director tenure extending to the 2028 Annual Meeting.
- Review of the "Withhold" vote count for director BJ Bormann, which was significantly higher than the other two nominees.
- Confirmation of the non-binding approval of executive compensation (Say-on-Pay).